International Assets Investment Management LLC Makes New $7.20 Million Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

International Assets Investment Management LLC acquired a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 58,548 shares of the specialty pharmaceutical company’s stock, valued at approximately $7,201,000.

A number of other institutional investors have also recently made changes to their positions in JAZZ. Vanguard Group Inc. raised its holdings in Jazz Pharmaceuticals by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock valued at $825,705,000 after buying an additional 29,960 shares during the last quarter. LSV Asset Management grew its stake in shares of Jazz Pharmaceuticals by 2.4% in the third quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company’s stock worth $307,055,000 after purchasing an additional 55,630 shares during the last quarter. FMR LLC increased its holdings in Jazz Pharmaceuticals by 8.1% during the 3rd quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock valued at $172,560,000 after purchasing an additional 100,349 shares during the period. Ameriprise Financial Inc. raised its position in Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,299,612 shares of the specialty pharmaceutical company’s stock valued at $168,222,000 after purchasing an additional 57,717 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its holdings in Jazz Pharmaceuticals by 28.1% in the 4th quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock worth $125,916,000 after buying an additional 224,865 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.1 %

Shares of NASDAQ:JAZZ opened at $109.85 on Tuesday. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38. The stock has a fifty day simple moving average of $115.98 and a two-hundred day simple moving average of $120.78. Jazz Pharmaceuticals plc has a 12-month low of $103.01 and a 12-month high of $146.70. The stock has a market capitalization of $6.92 billion, a price-to-earnings ratio of 22.65, a PEG ratio of 1.53 and a beta of 0.63.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1.01 billion. On average, research analysts anticipate that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now directly owns 8,364 shares in the company, valued at approximately $1,000,668.96. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CFO Philip L. Johnson purchased 12,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were purchased at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the transaction, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The disclosure for this sale can be found here. Insiders own 4.40% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on JAZZ. Truist Financial reissued a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Royal Bank of Canada reissued an “outperform” rating and set a $195.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. Barclays decreased their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $180.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $222.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, May 2nd. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $192.75.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.